Finding Disease Biomarkers for Early Diagnosis and Treatment

Finding Disease Biomarkers for Early Diagnosis and Treatment

Finding Disease Biomarkers for Early Diagnosis and Treatment

Identifying molecules that indicate disease, known as biomarkers, promises to significantly improve human health through early diagnosis and customized treatment. However, improved research instruments are needed to separate and identify specific molecules that make up these biomarkers.

Pacific Northwest National Laboratory (PNNL) developed an instrument that can process these complex samples rapidly and accurately, detecting rare yet important molecules for early disease diagnosis. This instrument combines two complementary analysis techniques in one instrument. It is called CoMet, short for Combined Orthogonal Mobility and Mass Evaluation Technology. No other single instrument on the market can do what CoMet does. It won an R&D 100 award from R&D Magazine in 2013.

PNNL and Agilent Technologies, a California-based measurement systems company with customers in more than 100 countries, collaborated to develop, engineer, and test the technology and validate its market need and value. In 2013, Agilent licensed the CoMet technology. The company introduced the instrument to its customers at the American Society for Mass Spectrometry conference in 2013 and began taking orders on its commercial model the following year.